Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-MOGAMULIZUMAB |
|---|
| ID | REG-MOGAMULIZUMAB |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
MAVORIC trial (Kim 2018, Lancet Oncol): mogamulizumab 28% ORR vs vorinostat 5% ORR in r/r MF/Sézary; PFS HR 0.53. Best response in Sézary syndrome (blood B2). NCCN cat 1 for r/r; emerging 1L for advanced Sézary syndrome where access permits. Skin AE management (drug rash ~25%, distinguishing from progression critical) requires dermatology partnership — not stand-alone hematology workflow.
Used By
Indication
IND-ATLL-2L-MOGAMULIZUMAB- IND-ATLL-2L-MOGAMULIZUMABIND-MF-ADVANCED-1L-MOGA- IND-MF-ADVANCED-1L-MOGA
Monitoring
MON-MF-SYSTEMIC- MON-MF-SYSTEMIC